Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction

Journal of the American College of Cardiology, Journal Year: 2022, Volume and Issue: 79(20), P. 2058 - 2068

Published: May 1, 2022

Sodium glucose cotransporter-2 (SGLT2) inhibitors improve cardiorenal outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and heart failure. SGLT2 also reduce the risk of cardiovascular mortality hospitalization for failure among mellitus a remote history myocardial infarction (MI). As result growing body evidence diverse disease states, hypothesized mechanisms action, it is reasonable to consider potential inhibition acute MI as well if initiated early after presentation. Whether these therapies are efficacious safe use course coronary remains relatively unexplored. Here, we describe contemporary data continuing gap considering following an morbidity mortality.

Language: Английский

---

Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions

Cardiovascular Research, Journal Year: 2022, Volume and Issue: 118(18), P. 3536 - 3555

Published: Aug. 24, 2022

Abstract Many patients with symptoms and signs of heart failure have a left ventricular ejection fraction ≥50%, termed preserved (HFpEF). HFpEF is heterogeneous syndrome mainly affecting older people who many other cardiac non-cardiac conditions that often cast doubt on the origin symptoms, such as breathlessness, or signs, peripheral oedema, rendering them neither sensitive nor specific to diagnosis HFpEF. Currently, management directed at controlling treating comorbid hypertension, atrial fibrillation, anaemia, coronary artery disease. also characterized by persistent increase in inflammatory biomarkers. Inflammation may be key driver development progression its associated comorbidities. Detailed characterization pathways provide insights into pathophysiology guide future management. There growing interest novel therapies specifically designed target deregulated inflammation therapeutic areas, including cardiovascular However, large-scale clinical trials investigating effectiveness anti-inflammatory treatments are still lacking. In this manuscript, we review role possible implications for trials.

Language: Английский

---

Dapagliflozin alleviates myocardial ischemia/reperfusion injury by reducing ferroptosis via MAPK signaling inhibition

Frontiers in Pharmacology, Journal Year: 2023, Volume and Issue: 14

Published: Feb. 20, 2023

Reperfusion is essential for ischemic myocardium but paradoxically leads to myocardial damage that worsens cardiac functions. Ferroptosis often occurs in cardiomyocytes during ischemia/reperfusion (I/R). The SGLT2 inhibitor dapagliflozin (DAPA) exerts cardioprotective effects independent of hypoglycemia. Here, we investigated the effect and potential mechanism DAPA against injury (MIRI)-related ferroptosis using MIRI rat model hypoxia/reoxygenation (H/R)-induced H9C2 cardiomyocytes. Our results show significantly ameliorated injury, reperfusion arrhythmia, function, as evidenced by alleviated ST-segment elevation, biomarkers including cTnT BNP pathological features, prevented H/R-triggered cell viability loss vitro. In vitro vivo experiments showed inhibited upregulating SLC7A11/GPX4 axis FTH inhibiting ACSL4. notably mitigated oxidative stress, lipid peroxidation, ferrous iron overload, reduced ferroptosis. Subsequently, network pharmacology bioinformatics analysis suggested MAPK signaling pathway was a target common treatment phosphorylation vivo, suggesting might protect reducing through pathway.

Language: Английский

---

Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial

Circulation, Journal Year: 2023, Volume and Issue: 148(10), P. 834 - 844

Published: Aug. 3, 2023

Sodium-glucose cotransporter-2 inhibitors reduce risk of hospitalization for heart failure in patients who have with preserved ejection fraction (HFpEF), but the hemodynamic mechanisms underlying these benefits remain unclear. This study sought to determine whether treatment dapagliflozin affects pulmonary capillary wedge pressure (PCWP) at rest and during exercise HFpEF.

Language: Английский

---

Biological and functional multimorbidity—from mechanisms to management

Nature Medicine, Journal Year: 2023, Volume and Issue: 29(7), P. 1649 - 1657

Published: July 1, 2023

Language: Английский

---